Prescription drug · ANDA
Fenofibrate NDC 63629-9474
Fenofibrate 160 mg/1 · Tablet, Film coated · Oral · Bryant Ranch Prepack
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 63629-9474-1 | 63629947401 | 90 TABLET, FILM COATED in 1 BOTTLE (63629-9474-1)Marketed from Nov 28, 2022 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Fenofibrate
- Generic name (nonproprietary)
- fenofibrate
- Active ingredients
- Fenofibrate — 160 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Bryant Ranch Prepack
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 076433
- Marketing start
- Listing expires
- Identifiers
- Product ID 63629-9474_fd9a26bd-2569-4358-8d1c-9baccd330f84SPL ID fd9a26bd-2569-4358-8d1c-9baccd330f84SPL set ID 67a0cee0-79be-472a-a2a3-3aee2410b58bRxCUI 349287UNII U202363UOS
- Pharmacologic class
- Peroxisome Proliferator Receptor alpha Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N463629947401followed by a unit qualifier and the quantityPackage 63629-9474-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Fenofibrate Tablets, USP are a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ). 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate Tablets, USP are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), t…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 076433
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Fenofibrate | Fenofibrate 54 mg/1 | Tablet, Film coatedOral | American Health Packaging | 60687-853 |
| Fenofibrate | Fenofibrate 54 mg/1 | Tablet, Film coatedOral | Golden State Medical Supply, Inc. | 51407-093 |
| Fenofibrate | Fenofibrate 160 mg/1 | Tablet, Film coatedOral | American Health Packaging | 60687-864 |
| Fenofibrate | Fenofibrate 160 mg/1 | Tablet, Film coatedOral | Bryant Ranch Prepack | 71335-0741 |
| Fenofibrate | Fenofibrate 54 mg/1 | Tablet, Film coatedOral | Rhodes Pharmaceuticals LLC | 42858-454 |
| Fenofibrate | Fenofibrate 160 mg/1 | Tablet, Film coatedOral | Rhodes Pharmaceuticals LLC | 42858-660 |